Algeta shows off impressive Alpharadin Phase III data
This article was originally published in Scrip
Executive Summary
Algeta has presented results from the Phase III ALSYMPCA study with Alpharadin (radium-223 chloride), which met its primary endpoint and was terminated ahead of schedule earlier this year so that patients in the placebo arm could be offered the treatment (scripintelligence.com, 7 June 2011). These data raise the bar for Exelixis, which has a rival drug candidate, cabozantinib, trailing in clinical development.